Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Researchers from University of Wisconsin, Department of Human Oncology describe findings in life sciences
July 16th, 2008
Current study results from the report, 'CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors,' have been published. "Antitumor effects of CD40 ligation appear to involve distinct antitumor effector cells in different experimental models. In this study, we tested whether T cells were required for antitumor effects of agonistic anti-CD40 mAb (alphaCD40) against immunogenic versus poorly immunogenic tumors," scientists writing in the journal Cancer Immunology, Immunotherapy report. "Treatment of mice bearing poorly immunogenic B16 melanoma and its more immunogenic variant, B16-hsp72.1, with alphaCD40 resulted in a...
Source: Vaccine Weekly (2008-07-16)
|
